We are thrilled to have launched a new journal exclusively dedicated to this extraordinary field, which is experiencing a renaissance: Psychedelics: The Journal of Psychedelic Pharmacology. Why start this new journal now and why is it needed? Advances in psychedelic research are making hallucinogen substances a new frontier in psychopharmacology. As the world experiences a mental health crisis and an addiction epidemic, there is an increasing need for innovative treatments in psychiatry. Psychedelics need to be given increased attention as a therapeutic strategy. How do they work at the most fundamental molecular levels? Can pathways elucidated through the actions of psychedelics become conceptually novel new avenues for psychiatric treatment? Our new journal will bring together scientists from multiple disciplines to advance psychiatry through innovation. We will set new directions in mental health, neurology, neuroscience, therapeutics, and human consciousness. Please join us in this unprecedented journey towards discovery and its translation into highly innovative treatments.  FOR EARLY ACCESS TO OUR CONTENT, GO TO OUR Early View-AOP PAGE.

Overview and Key Features of Psychedelics

Amidst a revolutionary surge in psychedelic research, Psychedelics sets out precisely to pioneer and consolidate the scientific understanding of psychedelic substances. We are committed to publishing high-caliber, rigorous research that explores the biological, clinical, psychological, and societal dimensions of psychedelics. We intend to catalyze and shape the psychedelic renaissance by fostering international collaboration, bridging disciplinary divides, and influencing policy and practice with evidence-based findings. As a platform in this burgeoning field, we aim to propel the dialogue and discovery surrounding psychedelics into uncharted territories, illuminating their profound potential and role in our society. Join us as we chart the course towards a psychedelic-informed future.

Psychedelics holds a panoramic lens in a field as vast and multi-dimensional as psychedelic research. Our scope is comprehensive, encompassing the full spectrum of psychedelic inquiry. From molecular mechanisms to therapeutic applications, historical insights to societal implications, we are committed to providing a forum for diverse voices and perspectives that inform our understanding of these potent compounds.

We invite submissions from all disciplines, embracing a broad spectrum of research methodologies. We are interested in fundamental neuroscience, biochemistry, pharmacodynamics, clinical studies, brain imaging, therapeutic interventions, psychological explorations of perception and consciousness, and sociological examinations of historical usage and cultural impact.

Our scope is as broad as the field itself. We aim to shed light on the profound complexity and potential of psychedelic substances as we generate a comprehensive repository of psychedelic knowledge. Join us as we traverse the innovative landscape of psychedelic science, charting the unknown and illuminating the future of this exciting field.

New insights into the mind and therapeutic potential of these remarkable compounds are being gained thanks to the psychedelic renaissance. As the first dedicated platform in this burgeoning field, the mission of Psychedelics is fourfold:

  • Promote Rigorous Research: Psychedelics aims to become a beacon for the rigorous and robust scientific exploration of psychedelic substances. We welcome experimental and observational studies, reviews, and meta-analyses that dissect psychedelics’ biochemistry, pharmacodynamics, therapeutic potential, and other material that can advance the field.
  • Bridge Disciplinary Boundaries: We aim to unite disparate disciplines by publishing cross-disciplinary research that connects molecular understanding with clinical, psychological, societal, and historical perspectives of psychedelic substances.
  • Foster Collaboration: As pioneers in the field, we are committed to fostering an international, collaborative community of researchers, clinicians, policymakers, and stakeholders. We aim to spark lively discourse, encourage knowledge sharing, and facilitate synergies.
  • Influence Policy and Practice: Our journal aspires to document the psychedelic revolution and shape it. By presenting clear, evidence-based findings, we aim to influence medical, legal, and societal perspectives towards psychedelics, ultimately leading to more informed policy and practice.

As we navigate these exciting and uncharted waters, we invite you to join us in our quest to understand the mysteries of psychedelics, their transformative potential, and their place in our society. Together, let us illuminate the path to a psychedelic-informed future.

At the heart of Psychedelics reside our unwavering core values: academic integrity, scientific rigor, passionate purpose, relentless innovation, inclusive and cross-disciplinary team science, and excellence. We serve as a global platform that celebrates the diverse tapestry of psychedelic research, welcoming contributions from every corner of the globe. Each manuscript that comes to us is evaluated solely on its merit and potential contribution to the field, unswayed by its geographical origin. In fostering this culture of fairness and respect, we strive to create a dynamic, equitable space that fuels the collective growth and understanding of psychedelics as a tool to better health.

Our major goal is to attain the highest levels of scientific achievement and that can only be based on transparency and honesty. Therefore, as an integral part of our mission to uphold the bedrock of scientific integrity, Genomic Press has instituted procedures to meticulously scrutinize any allegations that come into our purview, irrespective of their channel of emergence. Whether raised prior to publication or post-release, or when proffered by whistleblowers, these charges are met with rigorous examination. Our pledge to sustain scholarly excellence propels us to diligently investigate any suspicions of scientific malfeasance, which may run the gamut from academic fraud, recurrent manuscript submissions, spurious data creation or manipulation, to ethically dubious research participant interactions, contested authorship, falsified reviewer endorsements, and cloaked vested interests.

In this spirit all our papers will be subjected to plagiarism check for text and, as the technology evolves, also for figures.

While our operational ethos is chiefly harmonized with the principles articulated by the Committee on Publication Ethics (COPE), we retain the latitude to embark on divergent strategies when exigent circumstances call for such. This latitude may entail establishing a dialogue with the questioned authors’ academic institutions, funding agencies, or other germane oversight authorities for rigorous scrutiny.

As for amending the published record, we employ a contextually-based approach, executing modifications through either errata or retractions, based upon broad considerations: errata typically correct inadvertent errors in discrete aspects of published work that do not change the overall findings and conclusions. In contrast, the criteria for retraction may include any of the following: (a) evidence of calculated manipulation, (b) the level of correction would change the nature of the overall findings and conclusions, (c) extensive plagiarism, or (d) there is an overall lack of confidence in the work. We also support COPE’s observations that Editors consider retracting a publication if:

  • They have clear evidence that the findings are unreliable, either as a result of major error (eg, miscalculation or experimental error), or as a result of fabrication (eg, of data) or falsification (e.g., image manipulation).
  • It constitutes plagiarism.
  • The findings have previously been published elsewhere without proper attribution to previous sources or disclosure to the editor, permission to republish, or justification (ie, cases of redundant publication).
  • It contains material or data without authorization for use.
  • Copyright has been infringed or there is some other serious legal issue (e.g., libel, privacy).
  • It reports unethical research.
  • It has been published solely on the basis of a compromised or manipulated peer review process.
  • The author(s) failed to disclose a major competing interest (a.k.a. conflict of interest) that, in the view of the editor, would have unduly affected interpretations of the work or recommendations by editors and peer reviewers.

When deliberating on rescinding an article’s acceptance, initiating the retraction of an already disseminated piece, or emitting an editorial cautionary note, it is our standard protocol to engage in communications with the concerned authors’ institutions as part of our procedures. As supporters of COPE’s policies, we adhere to COPE guidelines in managing investigations of possible misconduct, which are accessible here). This document includes the following language “The COPE Code of Conduct for Journal Editors (Clause 11.4) notes that, in cases of suspected or alleged research or publication misconduct ‘editors should first seek a response from those suspected of misconduct. If they are not satisfied with the response, they should ask the relevant employers, or institution … to investigate.’ COPE therefore advises that investigations into possible misconduct should generally be undertaken by the researcher’s institution and not by editors. If a journal has published unreliable or fraudulent information, the editor has a duty to correct or retract this. However, responsibility for disciplining researchers and ensuring they do not commit further misconduct lies with their institution / employer. Therefore, even when faced with apparently strong evidence of misconduct (e.g. plagiarism or inappropriate image manipulation), and a clear need to correct the published record, editors should liaise with institutions and ensure they are informed.”

Peer review is the cornerstone of the scientific evaluation process, and it is widely used in evaluating research funding (grants) and research results (papers). We firmly believe in the integrity of the editorial process that is based on impartial peer review.

The peer review process can be configured in different ways, with the vast majority of journals worldwide adhering to one of three formats: (i) Single-blind peer reviews are anonymous only to the authors. Authors do not know the reviewers’ names or backgrounds, but reviewers know theirs. (ii) Both authors and reviewers in double-blind peer reviews are anonymous; only the editor knows their identities. A truly double-blind peer review process is hard to attain, as a knowledgeable review can infer authorship based on specific methods and areas of research and cited work. (iii) In open peer review the identity of the author and the reviewer is known by all participants, during or after the review process.

Psychedelics adheres to the single-blind peer review model, ensuring that authors do not know who the reviewers are. In contrast, reviewers have access to the authors’ identities. The single-blind anonymity allows reviewers to be honest without fear of criticism from an author; furthermore, knowing who the authors are allows the reviewer to use their knowledge of the authors’ previous research. This traditional and widely adopted format is the most prevalent in scientific publishing. This is also the same process used by most government funding agencies worldwide.

The content of Psychedelics will be entirely peer-reviewed. The only exception will be informational editorials, written by the Editor-in-Chief as broad and topical commentaries, and those will be clearly identified as Editorials.

All content submitted to Psychedelics, including original research, reviews, correspondence, and all other manuscript types, will be – without exception – sent by our editorial office to outside experts for single-blind peer review. To maintain the international makeup of Psychedelics from the outset, we typically send each submission to eight experts, inviting experts in such a manner that avoids all reviewers being in any one country. We aim to make editorial decisions based on at least three reviews, but if only two reviews are obtained, we may use them for an editorial decision.

Publishing with Psychedelics offers a distinct blend of benefits designed to champion your research and its impact. We guarantee a swift, meticulous, and personalized review process, ensuring your work is treated with the care and attention it deserves. Our commitment to global dissemination translates into a wide-reaching audience for your work, propelled further by our comprehensive press release strategy, providing worldwide access and visibility. In alignment with our dedication to equity and accessibility, we maintain a fair and transparent cost structure. our dedicated yet expansive focus on emerging research across multiple areas ensures your work will contribute to and thrive within the forefront of psychedelic science. Choose Psychedelics, where every piece of research is a step towards pioneering the future of psychedelic pharmacology and related sciences.

We are now registered with Crossref, providing all our publications with searchable DOI links. Applications are being made for Brain Medicine’s ISSN and E-ISSN. As a new and academically based and focused publication, we strive to build a robust portfolio of published articles to meet the criteria for inclusion in other databases. Upon reaching the minimum thresholds, our mission is to actively pursue indexing by prominent databases such as Emerging Sources Citation Index, Web of Science, Current Contents, Current Contents/Life Sciences, EMBASE/Excerpta Medica, MEDLINE/Index Medicus, Neuroscience Citation Index, PsycINFO, and Science Citation Index. Importantly, inclusion in these databases is retrospective. Consequently, even if your paper is submitted before our indexing, once achieved, your work will be indexed and electronically accessible through these databases.

Genomic Press is a signatory of the San Francisco Declaration on Research Assessment (DORA) and as such we support the adoption of multiple practices in research assessment. DORA’s first general recommendation is not to use journal-based metrics, such as Journal Impact Factors, as a surrogate measure of the quality of individual research articles, to assess an individual scientist’s contributions, or in hiring, promotion, or funding decisions.

The notion of a “journal impact factor,” alternately abbreviated as IF or JIF, conceived by Eugene Garfield, was created at the Philadelphia-based Institute for Scientific Information (ISI). The IF was originally created as a tool to help librarians identify journals to purchase, not as a measure of the scientific quality of research in an article. Broadly, the IF is indicative of a journal’s influence, as it has regularly assessed annually since 1975 for those journals enumerated in the Journal Citation Reports (JCR). This establishment, first identified as Thomson ISI, fell under the ownership of Thomson Scientific & Healthcare in 1992. A series of transactions in 2018 saw Thomson Reuters divest itself of ISI, transferring ownership to Onex Corporation and Baring Private Equity Asia. In the current epoch, Clarivate, an emergent corporation formed by these organizations, presides over the publication of the JCR.

The term “impact factor” is constituted by the quotient derived from dividing the total citations received in one year by articles published within the preceding two years, divided by the number of articles published within that same two-year timeframe. As an illustration, the highly regarded journal Cell (published by Cell Press, a subsidiary of Elsevier) boasted an impact factor of 66.850 for 2022. This number indicates that each scholarly piece published in 2020 and 2021 by Cell was cited, on an average scale, close to 67 times in the year 2022. It must be emphasized, however, that the computations for the impact factors for the year 2022 were only disclosed in June of the year 2023, for the calculus can only be performed post the thorough perusal and processing of all scholarly output for the year 2022 by the indexing company.

The journal impact factor (IF or JIF) is a metric index calculated by Clarivate that measures the number of citations articles published in a specific journal receive over two years, based on the Clarivate Web of Science index. This metric gauges a journal’s relative importance within its field, with higher impact factors indicative of higher prestige and influence. Despite its criticism for potentially encouraging malpractice, the use of impact factors for promotional decisions and research proposals by universities and funding agencies is common. For more information, refer to the article by EC McKiernan and colleagues (2019)[1].

As for Psychedelics, our Impact Factor will be determined after the first three years of publication.

[1] Source: Erin C McKiernan et al. Meta-Research: Use of the Journal Impact Factor in academic review, promotion, and tenure evaluations. Elife 2019 Jul 31;8:e47338. doi: 10.7554/eLife.47338.


Information is widely disseminated through social media nowadays. Therefore, Genomic Press will maximize the impact and reach of your research using different social media platforms.


We have crafted a dynamic social media approach, integrating five major platforms – Facebook, Twitter, LinkedIn, Instagram, and YouTube – each selected for their distinct strengths in information sharing and audience engagement.


With Facebook’s extensive user network, we can ignite engaging discussions about your work among a broad spectrum of audiences. Twitter, known for its real-time updates, lets us promptly broadcast your research highlights to a global assembly of academics, researchers, and enthusiasts.


LinkedIn provides a portal to a professional audience, offering your work visibility among industry pioneers, potential partners, and relevant organizations. Instagram’s visual-oriented platform facilitates converting complex research into easily understandable and impactful posts. YouTube, with its potential for video summaries and author interviews, presents your research in a captivating and comprehensive format.


Our sophisticated social media approach guarantees that your research is published and promoted effectively across diverse platforms, maximizing its dissemination, significance, and contribution to the global scientific community.

Publishing your research is just the starting point of its journey at Psychedelics. The true essence of scientific exploration lies in its broad dissemination, fostering a ripple effect within the scientific world and further afield. As part of our commitment to this cause, we harness the potential of press releases to elevate your work, ensuring your research achieves the visibility and acclaim it merits.

Every piece of research published by Psychedelics carries the capacity to elevate scientific understanding and promote human well-being, making their publicity a priority for us. We maintain robust partnerships with authors and their institutions, jointly developing compelling press releases for each significant article. These press releases encapsulate your research in a crisp, intriguing, and accessible narrative designed to attract a diverse readership. For institutions that prefer to manage their press releases, we will gladly synchronize our efforts with theirs, while continuing to create our own press releases unless advised otherwise.

To ensure that your work gets extensive exposure worldwide, our Press Releases will be disseminated by EurekAlert!, a nonprofit news-release distribution platform operated by the American Association for the Advancement of Science (AAAS, the publishers of Science) as a resource for journalists and the public. Established in 1996, EurekAlert! hosts news releases produced by universities, journal publishers, medical centers, government agencies, corporations, and other organizations engaged in all disciplines of scientific research, and those releases are widely used by journalists from all countries.

This initiative underpins our commitment to supporting your research journey and actively promoting your accomplishments. We are invested in providing your groundbreaking work with the platform it needs to stimulate discourse, inspire innovation, and contribute to improving our global scientific community.

Upon our launch in 2024, Psychedelics will allow readers and authors to subscribe to newsfeeds. This service will provide regular updates on newly published articles and advancements in the field, ensuring you stay informed about the latest research in psychedelic pharmacology.

Our inaugural Editor-in-Chief is Julio Licinio, MD, PhD, MBA, MS, a prominent figure in the field of psychiatry and neuroscience, who has amassed a wealth of achievements and contributions to his field. Dr. Licinio is the author of 327 publications listed in Pubmed; his h-index is 90, and his work has been cited 42,166 times. His research has been competitively funded at the federal level for 25 years in two continents. As a testament to his eminence and broad achievements, he has been honored with prestigious titles such as Fellow of the Australian Academy of Health and Medical Sciences, Matthew Flinders Distinguished Professor at Flinders University, and State University of New York Distinguished Professor​​. His dedication to advancing medical education is evident through his leadership in graduate training programs in translational investigation, which have significantly benefited physician-scientists across multiple prestigious institutions including UCLA, the University of Miami, and the Australian National University. He was also Dean of the College of Medicine, State University of New York Upstate Medical University, where he is currently a Distinguished Professor.​

His pioneering work in the pharmacogenomics of antidepressants, where he has delved into the genetic underpinnings of individual responses to psychotropic medications, highlights his significant experience in psychopharmacology​​. This experience is further exemplified by his groundbreaking research on leptin’s role in obesity and its potential implications for appetite control, endocrinology, and the brain’s response to pharmacological interventions​​​. His body of scientific work showcases his forward-thinking in applying psychopharmacological research for therapeutic advancements​.

With over 30 years at the helm of academic publishing, Dr. Licinio has been instrumental in the founding and ascension of four journals, guiding them from their foundational stages to prominence and high-impact status. In a remarkable span of the last seven years, he has skillfully edited and brought to light 44 articles authored by nine Nobel Prize recipients, prominently featuring 19 works by the distinguished Paul Greengard. Dr. Licinio’s adept leadership was pivotal in elevating the first journal he created, transforming it from an emerging entity to the leading journal in its field worldwide in just over a decade.

Similarly, we are curating our Editorial Board from a list of eminent international experts. Our Board will epitomize diversity in expertise, geographical representation, gender, experience, and ethnicity. Confirmed members of the Editorial Board include:

Lucie Bartova, Medical University of Vienna, 1090 Vienna, Austria

Laura Bohn, The Herbert Wertheim University of Florida Scripps Institute for Biomedical Innovation and Technology, Jupiter, Florida 33458, USA

Robin Carhart-Harris, Weill Institute for Neurosciences, University of California, San Francisco, California 94158, USA

Alex K. Gearin, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

Mark Geyer, University of California, San Diego, California 92093, USA

Gabriella Gobbi, McGill University, Montreal, Québec H3A 1A1, Canada

Javier González-Maeso, Virginia Commonwealth University, Richmond, Virginia 23298, USA

Steven Haggarty, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA

Emelie Katarina Svahn Leão, Federal University of Rio Grande do Norte (UFRN), Natal, RN 59078-970, Brazil

Bernard Lerer, Hadassah Medical Center, Hebrew University Jerusalem, Israel

Edythe London, University of California, Los Angeles, California 90095, USA

Charles Raison, University of Wisconsin-Madison, Madison, Wisconsin 53719, USA

Dusty Rose Miller, Vanderbilt University, Nashville, Tennessee 37212, USA

David E. Olson, University of California, Davis, California 95618, USA

Carol A. Paronis, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA

Jerrold F. Rosenbaum, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA

Stephanie Sillivan, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, USA

Michael A. Silver, University of California, Berkeley, California 94720, USA

At Genomic Press, we recognize the challenges researchers often encounter during the manuscript submission and publication processes. We strive to streamline this journey, allowing your focus to remain on creating and disseminating transformative research.

To promote consistency and transparency, we have developed a unified set of author guidelines for all Genomic Press journals, including Genomic Psychiatry and Psychedelics. All our publications will accept the same types of manuscripts and follow the same author instructions. We have designed this approach to enhance your experience, ensuring an efficient and seamless publishing process. For detailed guidelines on preparing and submitting your manuscript to Psychedelics, follow this link.

We warmly welcome you to our family of researchers! At Genomic Press and Psychedelics, we are dedicated to making the process of publishing your research as smooth as possible, fostering a path for your discoveries to impact the scientific community and the world at large. Stay tuned for more specific details about Psychedelics.

Stay tuned as we provide updated info for our launch

Scroll to Top

Contact US